Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fondaparinux.

Kiat T Tan1, Gregory Y H Lip

  • 1Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, England UK.

Current Pharmaceutical Design
|February 24, 2005
PubMed
Summary
This summary is machine-generated.

Fondaparinux, a novel anticoagulant, is effective for preventing deep vein thrombosis after orthopedic surgery. Its use is also being explored for acute coronary syndromes and other thromboembolic events.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence guided antiplatelet treatment: time to move from bench to bedside.

Thrombosis research·2009
Same author

Performing repeated noninvasive bedside measures of volume response to intravenous furosemide in acute pulmonary edema: a feasibility assessment.

Cardiovascular therapeutics·2009
Same author

Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.

Expert review of cardiovascular therapy·2009
Same author

Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.

Thrombosis and haemostasis·2009
Same author

Indications for the use of diagnostic implantable and external ECG loop recorders.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2009
Same author

Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicity-related clinical features.

Stroke·2009
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Area of Science:

  • Pharmacology
  • Anticoagulant Therapy
  • Thrombosis Prevention

Background:

  • Fondaparinux is the first approved pentasaccharide Factor X inhibitor.
  • It represents a significant advancement in anticoagulant therapy.

Purpose of the Study:

  • To review the pharmacology of fondaparinux.
  • To summarize clinical trials and arguments for/against its use.

Main Methods:

  • Review of existing literature on fondaparinux.
  • Analysis of clinical trial data.
  • Synthesis of evidence regarding efficacy and safety.

Main Results:

  • Fondaparinux demonstrates efficacy in preventing deep vein thrombosis in orthopedic surgery patients.
  • Ongoing evaluation for acute coronary syndromes and established thromboembolic events.

    • Conclusions:

    • Fondaparinux is a valuable anticoagulant with established efficacy in specific indications.
    • Further research is ongoing to expand its therapeutic applications.